In the STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme, hair loss was reported in 2.5% to 3% of adults taking Wegovy, compared to approximately 1% in the placebo group
Initially, the FDA issued complete response letters on October 22, 2024, and April 18, 2024, citing deficiencies classified as minor, and requested that the manufacturer address these with new and updated information and clarifications related to the drug substance, drug product, manufacturing, and microbiology
Some may take a bit longer, particularly if their dose increases are faster or their digestive system is more sensitive
Its important to report any concerns to our team